Neelima Kunam, MD
Psychiatry · Redlands, CANPI 1114269685
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $45,989 of the $58,597 with a category attached, or 78.5%. 30 manufacturers reported payments, led by Alkermes, Inc. at 53.8% of the total. Reporting peaked in 2022 at $21,352 and has fallen 96.8% since, to $679 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 380 payments — averaging $154.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$31K
- Idorsia Pharmaceuticals US Inc$10K
- Otsuka America Pharmaceutical, Inc.$9K
- AbbVie$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$944
- Takeda Pharmaceuticals U.S.A., Inc.$386
- plus $3K from 24 others
Across 77 payments — averaging $2695.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$207K
- AbbVie$681
What the payments were for
- Consulting fees$8501%
- Speaking & faculty fees$45,98978%
- Travel & lodging$3,6946%
- Food & beverage$7,88013%
- Education$1830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 48 | $31,498 |
| Idorsia Pharmaceuticals US Inc | 11 | $10,118 |
| Otsuka America Pharmaceutical, Inc. | 57 | $8,745 |
| AbbVie(2 entities) | 51 | $4,080 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 47 | $944 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $386 |
| Teva Pharmaceuticals USA, Inc. | 15 | $384 |
| Sunovion Pharmaceuticals Inc. | 28 | $352 |
| Neurocrine Biosciences, Inc. | 7 | $288 |
| Supernus Pharmaceuticals, Inc. | 15 | $284 |
| Johnson & Johnson | 16 | $270 |
| Lundbeck LLC | 17 | $242 |
| Ironshore Pharmaceuticals Inc. | 7 | $133 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $133 |
| E.r. Squibb & Sons, L.L.C. | 5 | $124 |
| Vanda Pharmaceuticals Inc. | 4 | $92 |
| Biogen | 2 | $85 |
| Bausch Health US, LLC | 4 | $81 |
| Axsome Therapeutics, Inc. | 2 | $58 |
| Adlon Therapeutics L.p. | 4 | $55 |
| Medtronic | 1 | $54 |
| Eisai Inc. | 2 | $30 |
| Neuronetics, Inc. | 1 | $29 |
| Tempus AI, Inc | 1 | $26 |
| Brainsway USA Inc | 1 | $25 |
| Janssen Scientific Affairs, LLC | 1 | $24 |
| Corium, LLC | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $13 |
| Merck | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,597 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 12 | $16,711 |
| Lurasidone Hcl | 15 | $8,996 |
| Bupropion XlBupropion Hcl | 34 | $6,342 |
| Paliperidone ErPaliperidone | 12 | $1,569 |
| Lamotrigine | 76 | $1,017 |
| Buspirone Hcl | 50 | $571 |
| Quetiapine Fumarate | 33 | $525 |
| Olanzapine | 50 | $459 |
| Carbamazepine | 12 | $401 |
| Fluoxetine Hcl | 24 | $380 |
| Trazodone Hcl | 48 | $375 |
| Ziprasidone Hcl | 11 | $366 |
| Mirtazapine | 29 | $326 |
| Duloxetine Hcl | 15 | $250 |
| Hydroxyzine Pamoate | 17 | $213 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $4,080 | $16,71112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Redlands
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.